Pharmaceuticals

Biocon's Yesafili, an interchangeable biosimilar to the $5.9B eye drug Eylea, launches in the US, promising major cost savings and market disruption.

Fresh off a $260M IPO, Seaport Therapeutics is advancing a de-risked pipeline for depression and anxiety, leveraging its novel platform to unlock new potential.

Lipocine's appointment of M&A veteran Michael Grissinger isn't just a new face on the board; it's a clear signal of a strategic pivot towards high-stakes partnerships.

With blockbuster sales for its MS drug BRIUMVI, TG Therapeutics is raising revenue targets and aggressively expanding its pipeline into new diseases.

Riding a wave of strong Q2 results, Supernus announces a merger of equals with Indivior, set to create a new, scaled player in CNS and addiction medicine.

Amid legal battles and policy shifts threatening the $100B 340B drug program, GPOs like HealthTrust are becoming critical navigators for hospital survival.

With its AI platform generating novel targets, Compugen advances a key ovarian cancer drug while partners AstraZeneca and Gilead push its discoveries forward.

Varda Space Industries adds a Pfizer legend to its board, signaling that the race to manufacture life-saving drugs in zero gravity is entering a new orbit.

The FDA has fast-tracked a novel peanut allergy therapy from Aravax, signaling a major shift in the multi-billion dollar race to find a lasting solution.

The first Animal Longevity Summit marks a pivotal moment, as research into pet aging and biotech investment converge to create a new frontier in healthspan.

A recall of a vital pet arthritis drug due to glass fibers reveals a history of quality control failures, forcing a difficult reckoning for pet owners and vets.

With cash dwindling and a pivotal trial result looming after a recent failure, Vistagen brings a seasoned drug developer aboard to navigate the turbulence.

With Phase 3 results for Levosimendan imminent and its cash runway secured, Tenax Therapeutics faces a make-or-break moment in the PH-HFpEF space.

Amid production stoppages from extreme weather, nuclear operator Orano reveals a complex financial picture and a bold strategy for US expansion and diversification.

Karyopharm plans an accelerated FDA filing for its selinexor combo in myelofibrosis. The move hinges on a key surrogate endpoint and a race against competitors.

U.S. sugar demand remains surprisingly strong, but a perfect storm of health trends and weight-loss drugs like Ozempic threatens a $55 billion upheaval.

With $217M in the bank, SAB Biotherapeutics has silenced liquidity fears. Now, all eyes are on its novel T1D drug and the unproven promise of its cow-powered tech.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

New patents in Europe and Australia grant Savara long-term protection for a vital new therapy, offering hope to patients with a rare, debilitating lung disease.

MIRA Pharmaceuticals moves two novel drug candidates closer to human trials, a key de-risking event for investors eyeing the massive pain and obesity markets.